The recently discovered 150-cavity (formed by loop residues 147-152, N2 numbering) adjacent to the enzymatic active site of group 1 influenza A neuraminidase (NA) has introduced a novel target for the design of next-generation NA inhibitors. However, only group 1 NAs, with the exception of the 2009 pandemic H1N1 NA, possess a 150-cavity, and no 150-cavity has been observed in group 2 NAs. The role of the 150-cavity played in enzymatic activity and inhibitor binding is not well understood. Here, we demonstrate for the first time that oseltamivir carboxylate can induce opening of the rigid closed N2 150-loop and provide a novel mechanism for 150-loop movement using molecular dynamics simulations. Our results provide the structural and biophysical basis of the open form of 150-loop and illustrates that the inherent flexibility and the ligand induced flexibility of the 150-loop should be taken into consideration for future drug design.
The recently discovered 150-cavity (formed by loop residues 147-152, N2 numbering) adjacent to the enzymatic active site of group 1 influenza A neuraminidase (NA) has introduced a novel target for the design of next-generation NA inhibitors. However, only group 1 NAs, with the exception of the 2009 pandemic H1N1 NA, possess a 150-cavity, and no 150-cavity has been observed in group 2 NAs. The role of the 150-cavity played in enzymatic activity and inhibitor binding is not well understood. Here, we demonstrate for the first time that oseltamivir carboxylate can induce opening of the rigid closed N2 150-loop and provide a novel mechanism for 150-loop movement using molecular dynamics simulations. Our results provide the structural and biophysical basis of the open form of 150-loop and illustrates that the inherent flexibility and the ligand induced flexibility of the 150-loop should be taken into consideration for future drug design. I nfluenza virus causes epidemics and pandemics, which severely impair public health [1] [2] [3] [4] [5] . Two of the major pandemics of the last century were caused by N2 containing influenza viruses: H2N2 (Asian flu) and H3N2 (Hong Kong flu) 1 . Recent outbreaks of H3N2 and H1N2 swine influenza viruses-caused human febrile respiratory illness in the United States highlight the importance of this subtype in influenza epidemics [6] [7] [8] . Besides H1N1, the H3N2 subtype is the major causative agent of severe epidemics and is critical for vaccine development 9 . Therefore a comprehensive understanding of N2 containing viruses is important for preparedness against highly transmissible influenza viruses.
Hemagglutinin (HA) and neuraminidase (NA) are the two major surface glycoproteins responsible for initiating influenza virus infection [10] [11] [12] [13] and virus release [14] [15] [16] , respectively. HA and NA of influenza A viruses are divided into subtypes based upon their distinct antigenic properties: seventeen for HA (H1-H17) and ten for NA (N1-N10) [17] [18] [19] . Among the influenza A viruses, only N1 and N2 have been found in human isolates responsible for pandemics and recurrent annual epidemics. With the exception of N10, recently identified in a bat influenza A virus genome, the nine NA alleles are classified into two groups according to phylogenetic analysis and structure. Group 1 NA comprises N1, N4, N5 and N8, whereas group 2 comprises N2, N3, N6, N7 and N9 20 . 3-D structures reveal the distinct conformations of the areas adjacent to the enzymatic active site between group 1 and group 2 members though the active site structures are virtually identical among all the NAs 20 . For typical N1 subtypes (but not for the 2009 H1N1 pandemic N1), the crystal structures reveal a 150-loop (formed by amino acids 147-152, N2 numbering) that adopts an open conformation forming an additional 150-cavity adjacent to the active site. Previously, no group 2 NAs have been crystallographically shown to have a 150-loop in an open conformation, although all-atom molecular dynamics simulations indicate that N2 may be able to adopt such a configuration in solution 21 . The recently discovered 150-cavity is currently being explored as a novel target for group 1 specific influenza NA inhibitors 20, 22 . Detailed structural analyses demonstrate that residue 147 plays an essential role in the conformation of the 150-loop. Recently, our group has shown that the N5 structure contains an extended 150-cavity resulting from the unique residue N147 23 . In the solved N2 structures, a salt bridge between D147 and H150 contributes to a rigid closed 150-loop 24 . Previous molecular dynamics simulations show that the D147-H150 salt bridge greatly stabilizes the closed 150-loop conformation and that loss of this salt bridge reduces the rigidity of the 150-loop 21 . D147 is prevalent in N2, but rarely found in other types of influenza NA 23 . Compared with N2 containing D147, the flexibility of the 150-loop of 2009 H1N1 NA (G147) is much higher 21 , although the structure of 2009 H1N1 NA also presents a deficient 150-cavity in its crystal structure 25 . Since NA plays an essential role in the release of new influenza virions from host cells, inhibition of NA compromises the ability of progeny virions to spread to uninfected cells. Oseltamivir (Tamiflu) and zanamivir (Relenza) are two commercially available NA-targeted competitive inhibitors, which act against both group 1 and group 2 enzymes as well as influenza B NA 16 . The open 150-loop of group 1 NAs has been found to adopt a closed conformation upon binding of zanamivir, however for oseltamivir carboxylate this effect depends on both inhibitor concentration and soaking time dependent 20 . The crystal structures of typical group 1 NAs in complex with oseltamivir carboxylate display two 150-loop conformations, indicating a two-step process of oseltamivir carboxylate binding. Molecular dynamics simulations of the free and oseltamivir carboxylate-bound forms of tetrameric N1 suggest a rapid loop switching motion, which demonstrates the flexibility of the 150-loop 26 . In contrast, in the crystal structures of typical group 2 NA-inhibitor bound complexes, the 150-loops always adopt closed conformation 20, [27] [28] [29] . Also, it is noteworthy that zanamivir always induces the closed conformation 20, 27 , whether the target is a group-1 or group-2 NA. Moreover, previous reports showed that R152K mutant in flu B lead to zanamivir and oseltamivir resistance 30, 31 , which suggests that 150-loop may also play a role in inhibitor binding.
Here we report a novel half open 150-loop in the crystal structure of a typical group 2 NA for the first time. This suggests that inhibitors targeting the 150-cavity may also effective target group 2 influenza NAs. Furthermore, we demonstrate with molecular dynamics simulations that the protonation state of inhibitors and N2 H150 play an important role on the movement of the 150-loop. Comparison of the differences between oseltamivir carboxylate and zanamivir binding to N2 illustrates the importance of the inhibitor C4 group (zanamivir numbering), providing considerable value for influenza inhibitor design.
Results
Oseltamivir carboxylate induced opening of the rigid N2 150-loop: the first open 150-cavity structure of group 2 NA. Sequence alignment shows that D147 is commonly found in N2 21, 23 . D147 can form a rigid salt bridge with H150, which plays an important role in holding the N2 150-loop in a closed conformation (PDB 1NN2) 24 . Thus, all the N2 crystal structures in the PDB database contain a rigid closed 150-loop. The free N2 observed in our experiment also presents a closed 150-loop (hereafter referred to as ''Free N2'') (Fig. 1a) .
However, upon soaking with oseltamivir carboxylate, we found that the rigid N2 150-loop can actually be opened (Fig. 1a) . Our crystal structure data indicates that the conformation of the N2 150-loop is dependent on the concentration of oseltamivir carboxylate (Fig. 1a) . Specifically, N2 presents an open 150-cavity when soaking crystals in 20 mM oseltamivir carboxylate for 1 hour (hereafter referred to as ''N2-oseltamivir open form''), while it shows the same conformation as in the free N2 when soaking into 40 mM oseltamivir carboxylate for 30 min (hereafter referred to as "N2-oseltamivir closed form") (Fig. 1a) . An influence of oseltamivir carboxylate concentration and soaking-time on the 150-loop conformation has also been observed in both N1 and N8 (Fig. 1a) , indicating that oseltamivir carboxylate has great influence on the conformation of the 150-loop. When using typical group 1 NA N1 (PDB 2HTY) and N8 (PDB 2HT5) 20 (Fig. 2b) . To investigate the importance of the D147-R107 intermolecular interaction in maintaining the open conformation of the N2 150-loop, D147 was replaced by glycine. Although the crystal of N2-G147 was soaked in the same condition as N2-oseltamivir open form, the 150-loop of the N2-G147-oseltamivir carboxylate complex still adopts a closed conformation identical to that of free N2 with D147 (Fig. 2c) . Specifically, the glycine does not have a side chain, so it cannot form hydrogen bond with R107 in neighboring molecule to further stabilize the 150-loop in an open conformation. Still, the side chain of N2-G147 H150 is flexible and adopts two conformations, in one of these conformations the H150 ND1 forms hydrogen bond with the oxygen atom of the G147 main chain, stabilizing a closed 150-loop conformation (Fig. 2c) . Additionally, the interaction between the side chain of D151 and the amino group of oseltamivir carboxylate is another factor that stabilizes the 150-loop in a closed conformation. In the N2-oseltamivir closed form structure, the amino group of oseltamivir carboxylate forms a hydrogen bond with the side chain of D151, at a distance of 3.26 Å (Fig. 2d) . While in the N2-oseltamivir-open structure, there is no interaction between the OD1 on the side chain of D151 and the amino group of oseltamivir carboxylate, with a distance of 8.23 Å (Fig. 2d) . Mechanism for oseltamivir carboxylate induced opening of the N2 150-loop. The crystal structures of N2 in complex with oseltamivir carboxylate and zanamivir were determined at pH 9.0, while the pKa values of the oseltamivr amino group and zanamivir guanidino group are 7.75 and 13 32 , respectively. Thus, the amino group of oseltamivir carboxylate should be neutral approximately 94.7% of the time while the guanidino moiety in zanamivir should be positively charged almost 99.9% of the time according to the HendersonHasselbach equation. The pKa of H150 in the closed 150-loop conformation is 1 pK unit higher than that in the open conformation as predicted by H11 33 . This indicates that H150 is more likely to be protonated in the closed conformation compared to the open conformation. To explore the mechanism of how inhibitors influence conformational changes of the 150-loop we performed three separated 200 ns molecular dynamics simulations (MDs) for tetrameric N2 with different protonation states of H150 and the amino group of oseltamivir carboxylate. One 200 ns MDs with zanamivir and one 200 ns MDs without any ligand were also performed (Table 1) .
In the OST-NH3-H150-Pos system, the C4 amino group of oseltamivir carboxylate and H150 are all positively charged. The 150-loop remains closed for 98.1% of the conformations sampled in the simulation ( Table 2 , Supplementary Fig. S1 ). The positively charged oseltamivir carboxylate amino group forms a hydrogen bond with the D151 side chain, which stabilizes the closed 150-loop conformation. The salt bridge between D147 and H150 contributes greatly to a closed 150-loop ( Supplementary Fig. S1 ).
In the OST-NH2-H150-Pos system, the oseltamivir carboxylate C4 amino group is neutral and H150 is positively charged. During the simulation, an open 150-cavity can be observed in all four chains and 40.8% of the configurations present a 150-cavity volume larger than 40 Å 3 (Table 2 ). Specifically, in chain A and chain D, the 150-loop started from a closed form, opened for a while, resulting in the formation of a 150-cavity, and then closed again, leading to absence of the 150-cavity. In the other two chains the 150-loop also opened ( Supplementary Fig. S2 ). The open and closed conformation of the 150-loop are directly related to the interaction between D147 and H150 ( Supplementary Fig. S2 ). Compared with the OST-NH3-H150-Pos system, the deprotonated amino group of oseltamivir carboxylate exerts a significant effect on 150-loop opening. The interaction between the amino group of oseltamivir carboxylate and the side chain of D151 is almost completely lost (Fig. 3a) which results in increasing flexibility of the 150-loop. The open and closed conformation of the 150-loop and environmental change of H150. Histidine is sensitive to environmental changes, so when oseltamivir carboxylate influences the rigid closed 150-loop structure, H150 may lose a proton which will reduce the interaction between D147 and H150, and further lead to the 150-loop open.
To validate the above hypothesis, we performed a MD simulation for the OST-NH2-H150-Neu system. In this system, both the amino group of oseltamivir carboxylate and the H150 imidazole side chain are in neutral states. A statistical analysis shows that the 150-cavity with a volume larger than 40 Å 3 occurs during 60.1% of the simulation (Table 2) , which is 19.3% and 58.2% larger than the OST-NH2-H150-Pos system and OST-NH3-H150-Pos system, respectively. The 150-loop opening is accompanied by the loss of the D147-H150 interaction in all four chains, although different behaviors can be observed in different chains and at specific times. In chain A, the 150-cavity volume decreased due to the orientation of R430. In chain B, the side chain of D147 failed to interact with R107 in the neighboring molecule, and then D147 and H150 formed weak hydrogen bonds again leading to the reformation of a closed 150-loop conformation (Supplementary Fig. S3 ). In chain D, the 150-loop opening process was observed in a similar manner observed in crystal soaking experiments (Fig. 3b) . After 40 ns, the interaction between the oseltamivir carboxylate amino group and D151 was lost (Fig. 3b) enabling the 150-loop to be more flexible. The interaction between D147 and H150 is reduced as a result of deprotonation of H150, thereby increasing the flexibility of D147. Then the side chain of R107 in the neighboring molecule has the opportunity to form salt bridge with D147 enabling the 150-loop to form a stable open conformation.
To validate the effect of the protonation state of H150 on the flexibility of the 150-loop, the FREE-H150-Neu system with H150 in the neutral state was set up. Instantaneous opening of the 150-cavity can be observed in all four of the chains. Specifically, in chain B, C and D, the 150-cavity opened for a short time and then closed again. For chain A, the cavity remains open for a longer time (Supplementary Fig. S4 ). 72% of the conformations have a 150-cavity smaller than 40 Å 3 , which is much larger than the closed conformation population in OST-NH2-H150-Neu (39.9%) ( Table 2 ). This indicates that without oseltamivir carboxylate, N2 prefers a closed 150-loop conformation. Although the interaction between D147 and H150 becomes weaker as the deprotonation of H150, hydrogen bonds such as R156-D151, Q136-H150 and T148-T439 also contribute to a closed 150-loop conformation (Fig. 3a) .
The guanidino group of zanamivir is virtually always positively charged due to its high pKa. Thus, in the ZMR-H150-POS system, the guanidino group and H150 are both set as positively charged. During the simulation, 97.8% conformations sampled in this trajectory has a 150-cavity smaller than 40 Å 3 . The 150-loop remains closed almost throughout the entire simulation ( Supplementary Fig. S5 ), and has strong interactions with zanamivir. Compared with oseltamivir carboxylate, the hydrogen bond occupancy between zanamivir and D151 is stronger (Fig. 3a) , which indicates that zanamivir has a higher avidity with the 150-loop. Moreover, the N2-inhibitor complex structure clearly shows that the interaction between the zanamivir guanidino group and neighboring residues (less than 3.5Å ) is stronger than that of the oseltamivir carboxylate amino group (Fig. 3c) . Specifically, the zanamivir guanidino can bind to four residues (E119, D151, W178 and E227), while the amino group of oseltamivir carboxylate can only interact with two residues (E119 and D151). The interactions between zanamivir and the main chain of the 150-loop also help to maintain the closed 150-loop conformation. The structure and simulation data suggest that the proper size and charge of the C4 moiety plays a critical role in determining 150-loop dynamics upon ligand binding.
Discussion
The influenza NA 150-cavity was first observed in group 1 NAs, and several group 1 specific inhibitors were subsequently designed to target this 150-cavity 22 . An open 150-loop has never been observed in X-ray crystallography experiments with group 2 NAs, especially in N2 containing a D147-H150 salt bridge, although simulation work suggested N2 may be able to adopt such a configuration in solution dynamics 21 . In this report, we demonstrate for the first time that the N2 150-loop can adopt a half-open conformation in its crystal structure. Furthermore we have carried out extensive molecular dynamics simulations in order to elucidate mechanisms of 150-loop motion.
The free N2 crystal structure possesses a salt bridge between D147 and H150, which is one of the key factors to determine the rigidity of its 150-loop. However, this rigid interaction can be broken under the condition of high concentrations oseltamivir carboxylate. With the exception of N5, which contains N147, all other types of NA possess G147. It can be inferred that the 150-loop should be more flexible with G147 in place of D147. Alternatively, the conformation of the 150-loop in these NAs should be more easily influenced by extrinsic factors. It seems that both group 1 and group 2 NAs are able to adopt an open 150-cavity under certain conditions. From this perspective, the conformation of the 150-loop may not be a true group specific feature which is consistent with previous molecular dynamics simulation results 21 . This notion can also be supported by the 150-cavity deficiency in the atypical group 1 member, 2009 pandemic N1 25 . It is worthy to note that an open 150-cavity in all types of NA has never been observed in the presence of zanamivir and it has been confirmed that zanamivir remains effective against oseltamivir-resistant viruses. Based on analysis of the complex structures of N2 and . Whearas the avidity of zanamivir is affected less by the IR and IRHY mutations as it is able to maintain hydrogen bonds to the 150-loop. Moreover, a R152K mutation in flu B results in oseltamivir and zanamivir resistance 30, 31 demonstrating that the interactions between key 150-loop residues in the 150-loop and inhibitors play an important role in high avidity binding. Therefore, increasing the hydrogen bonds between NA inhibitors and residues in the 150-loop may help to overcome drug resistance. Additionally, it is difficult for the zanamivir guanidino group to lose its charge due to its high pKa, and the positively charged guanidino group has a high affinity for the 150-loop.
In conclusion, this study demonstrates the inherent flexibility of the 150-loop and the importance of inhibitor protonation state on influencing active site conformations. The open 150-cavity discovered in group 2 NA suggests that protein active site conformations can be greatly influenced by introduction of a ligand. Thus, both intrinsic protein dynamics and ligand induced protein dynamics should be considered in the future antiviral drug design.
Methods
Recombinant NA production. NA was prepared in baculovirus expression system as previous reported 1425 . cDNA encoding amino acid residues 83-469 of p57N2 (1957 Asian pandemic H2N2 NA, Sequence GenBank accession No. M18648.1) were cloned into the baculovirus transfer vector pFastBac1 (Invitrogen), with a GP67 signal peptide, a 6X histag, a tetrameric sequence and a thrombin cleavage site at the N terminus. A point mutation corresponding to G147 was introduced by site directed mutagenesis based on the p57N2 sequence. Recombinant baculovirus was prepared based on the manufacturer's protocol (Invitrogen). Sf9 cells were used to prepare recombinant baculovirus.
Protein crystallization and inhibitor soaking assays. Protein concentrations were determined using a BCA protein assay according to the manufacturer's instructions (Pierce). Crystallization screens were initiated using commercial kits (Hampton Research). All crystallizations were performed using the hanging drop vapor diffusion technique. The N2 wild type and N2-G147 crystals were observed in PEGRx I 27 Data collection, structure determination, refinement and analysis. All crystals were soaked in cryoprotectant (reservoir solution supplemented with 20% glycerol), then flash-cooled and maintained at 100 K in a cryostream. Diffraction data for the free p57N2 native structure were collected at KEK beamline NE3A, while the data for N2 soaked with oseltamivr carboxylate and zanamivir were collected at SSRF beamline BL17U. Diffraction data were processed and scaled using HKL2000 35 . Data collection and processing statistics are summarized in Table 3 . The structure of p57N2 was solved by molecular replacement using the A/TOKYO/3/1967 H2N2 N2 molecule (PDB 1IVG) 36 as the search model with Phaser 37 in the CCP4 program suite 38 . The other datasets were determined by molecular replacement using the solved N2 structure. Extensive model building was performed by hand with COOT 39 , and restrained refinement was performed using REFMAC5 40 .
Further rounds of refinement were performed using the PHENIX package 41 . The final structures displayed good stereochemistry (Table 3) , as assessed by the program PROCHECK 42 . Structural figures were prepared with PyMOL (http://www.pymol.org/). Molecular dynamics simulations. Five simulation systems were built up and designated as OST-NH3-H150-Pos, OST-NH2-H150-Pos, OST-NH2-H150-Neu, ZMR-H150-Pos, and FREE-H150-Neu (Table 1) . Atomic coordinates of systems OST-NH3-H150-Pos, OST-NH2-H150-Pos, and OST-NH2-H150-Neu were taken from the crystal structure of the N2-oseltamivir closed form complex; FREE-H150-Neu were taken from the crystal structure of the free N2 and ZMR-H150-Pos were taken from the crystal structure of the N2-zanamivir complex (PDB 3TIC) 27 . NA tetramers were used in each system. Protonation states of H150 and states of ligand were assigned as shown in Table 1 . Water molecules and calcium ions in crystal structures were retained. RESP 43 charge of OST and ZMR were generated using antechamber 44 after calculation by Gaussian09 45 (HF/6-311G**). Force fields for OST and ZMR were generated based on general AMBER force field in amber package 43 . Then the system was setup using AmberTools. Amber ff99SB force field was applied to proteins 46 . The calcium was parameterized in the classical force field. TIP3P waters were added to solvate each system with a boundary of 8 angstroms away from any protein or ligand atoms 47 . Counterions were added to neutralize each system. The system details can be found in the Supplementary information (Supplementary Table 1 ). Then the topology of amber format was transformed to GROMACS readable format.
Simulations were performed using the GROMACS 4.5.3 package 48 . To alleviate any steric clashes, the initial structures were minimized using the steepest descents method with a force tolerance of 10 kJ mol 21 nm
21
. Non-hydrogen protein atoms, main chain atoms and protein a-carbon atoms were progressively restrained with a force constant of 1000 kJ mol 21 nm 21 . After energy minimization, the systems were heated to 310 K with position restraints on non-water atoms. The temperature was controlled using the V-rescale method with a coupling time of t T 5 0.1 ps and the pressure was maintained at 1 bar using Berendsen barostat with t p 5 0.1 ps and a compressibility of 4.5 3 10 25 bar. Long range electrostatic interactions were calculated using the particle-mesh Ewad (PME) algorithm 49, 50 . The LINCS 51 algorithm was used to constrain hydrogen bond lengths. Further three 500 ps long equilibration runs were position restrained during the whole equilibration process. Finally, 200 ns MD production runs were performed for each of the five tetramer systems. The time step for integration was set to 2 fs. The coordinates of the systems were saved every 10 ps.
Population analysis based on 150-cavity. Conformations in each chain were extracted by an interval of 100 ps from the trajectories for 150-cavity volume calculation. The volume of 150-cavity was measured using the pocket volume measuring algorithm POVME 52 . The volume inclusion sphere that defines the 150 cavity was a single sphere that encompassed the 150-cavity in the widely investigated group 1 neuraminidase (PDB 2HU0) 20 . Each conformation extracted was aligned to 2HU0, and POVME algorithm neglected the volume occupied by atoms within the 150-cavity sphere.
Hydrogen bond statistics and RMSD calculation. VMD 53 was used to calculate the hydrogen bonds between two groups or residues. Hydrogen bond distance cutoff was set to 3.5 Å and angle was set to 20 degrees. VMD was also used to calculate the RMSD of 150-loop in crystal structures. All a-carbon atoms were superimposed at first, and then the RMSD of a-carbon atoms in the 150-loop was calculated. Only Ca atoms were used to calculate RMSD values.
